PYPD PolyPid Ltd Forecast, Technical & Fundamental Analysis
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology... Show more
PYPD is expected to report earnings to rise 11.43% to -38 cents per share on November 11
Q3'26
Est.
$-0.39
Q2'26
Beat
by $0.05
Q1'26
Beat
by $0.70
Q4'25
Missed
by $0.08
Q3'25
Missed
by $0.04
The last earnings report on August 12 showed earnings per share of -34 cents, beating the estimate of -40 cents. With 3.58K shares outstanding, the current market capitalization sits at 103.59M.
A.I. Advisor
published General Information
General Information
a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes
A.I.dvisor indicates that over the last year, PYPD has been loosely correlated with LSTA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if PYPD jumps, then LSTA could also see price increases.
PYPD's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for PYPD moved out of oversold territory on July 22, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In of the 28 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on PYPD as a result. In of 132 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PYPD just turned positive on August 05, 2026. Looking at past instances where PYPD's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
PYPD moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PYPD crossed bullishly above the 50-day moving average on August 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PYPD advanced for three days, in of 215 cases, the price rose further within the following month. The odds of a continued upward trend are .
PYPD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 91 cases where PYPD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PYPD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PYPD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.231) is normal, around the industry mean (20.143). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (444.692).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PYPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
